---
schema_version: "secwatch.filing_event.v1"
accession: "0001217234-23-000094"
form_type: "8-K"
ticker: "CDNA"
cik: "0001217234"
company_name: "CareDx, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T05:55:42.411515+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CareDx Q1 revenue $77.3M (-3% YoY); withdraws 2023 guidance on billing article uncertainty

## Summary
- Record test volumes 49,900 (AlloMap/AlloSure), up 17% YoY; testing services revenue $61.8M.
- GAAP net loss $23.7M ($0.44 loss per share); adjusted EBITDA loss $6.4M.
- Patient & Digital Solutions revenue $8.6M, up 39% YoY; cash $285.9M, no debt.
- Withdrew 2023 revenue guidance due to MolDX Billing Article revisions in March and May 2023.
- Delayed submission of ~$8.9M in AlloSure Kidney Medicare tests from Q1 to Q2.

## SEC filing metadata
- accession: 0001217234-23-000094
- form_type: 8-K
- ticker: CDNA
- cik: 0001217234
- company_name: CareDx, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1217234/000121723423000094/0001217234-23-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1217234/000121723423000094/cdna-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001217234-23-000094
- JSON: https://secwatch.observer/filing/0001217234-23-000094.json
- Plain text: https://secwatch.observer/filing/0001217234-23-000094.txt

## Key facts
- Earnings Releases
  CareDx, Inc. reported the first quarter ended March 31, 2023 results: revenue $77.3 million, net income net loss of $23.7 million, EPS basic and diluted net loss per share of $0.44.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $77.3 million
  - Net income: net loss of $23.7 million
  - EPS: basic and diluted net loss per share of $0.44
  - Result: reported results
  source text: test results for AlloMap® and AlloSure® of approximately 49,900 tests, growing year-over-year by 17%, and exceeding year-over-year market growth of 10%. • Reported revenue of $77.3 million, a decrease of 3% year-over year. This excludes approximately $8.9 million in revenue associated with approximately 3,200 AlloSure Kidney Medicare tests that the Company did not
  evidence_url: https://www.sec.gov/Archives/edgar/data/1217234/000121723423000094/0001217234-23-000094-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.